REBUILDComposition corporelle et fonction musculaire dans le diabète de type 2 sous thérapie par agoniste du récepteur GLP-1

This study aims to understand how certain diabetes medications, like semaglutide (Ozempic) and tirzepatide (Mounjaro), affect older adults with type 2 diabetes, especially those at risk of losing muscle mass and strength. The research focuses on patients with additional health challenges like obesity, kidney disease, or heart conditions. These medications are known for helping control blood sugar and promoting weight loss, but there are concerns about potential muscle loss, which can lead to frailty and other serious health issues. By understanding the effects of these drugs on muscle and bone health, this study seeks to provide valuable insights that could enhance treatment plans and improve the quality of life for older adults with diabetes. Participants in the study will start taking one of the specified diabetes medications, and researchers will monitor changes in their body composition, muscle mass, and physical function. Advanced imaging techniques like MRI will be used instead of traditional methods to provide a more detailed picture of muscle and fat distribution. The study will also assess muscle strength and function, which are crucial for predicting potential health outcomes. The findings aim to help healthcare providers make better-informed decisions when prescribing these medications, ensuring that patients maintain muscle health and reduce risks of falls or fractures.